Dr. Hoimes presented the initial results of EV-103 with enfortumab vedotin combined to pembrolizumab in 1st line cisplatin ineligible mUC . Very promising ORR of 71% and 13% CRs. #ESMO19 MOC Brasil

Enfortumab Vedotin showing a significant 30% reduction in the risk of death compared to chemotherapy in chemo and immune therapy pretreated advanced urothelial cancer. RR=40%. A new class of drug + significant OS means this will now be widely used globally IMO NEJM ASCO #GU21

#ESMOTAT21: Characterisation of Toxicity Profiles of Immune and Molecularly Targeted Agents in Phase I and II Studies: Overall, more #adverseevents were reported with #targetedtherapies than with #immunotherapy Gustave Roussy ow.ly/TgSd50DMHSj

It is to be applauded the compromise of European Urology with the readers by publishing this opinion piece. Of course the authors (Vinay Prasad MD MPH) prestige had most likely some influence. Completely recommended quick lecture about #olaparib in #prostatecancer

Important work by Marco Moschini EAU Young Academics detection of VH with TURBT important for Rx planning and trial inclusion UroToday.com Eur Urol Focus eu-focus.europeanurology.com/article/S2405-…

A phase 3 trial with a 2x2 factorial design of abiraterone acetate + prednisone and/or local radiotherapy in men with de novo #mCSPC. First results of #PEACE1 presented by Karim Fizazi Gustave Roussy. #ASCO21 written coverage by Christopher Wallis (he/him/his) Vanderbilt Urology > bit.ly/3g2SyCH

RII of eradfitinib (FGFR) vs eraftinib+cetrelemab (PD1) in FGFR+ve 1st line UC (cis-ineligible). Combo RR=68% vs 33% (n=48). PFS and OS immature.  AEs followed expectations. Early data suggests the combo may beat chemo. Larger trials warranted. #ESMO2021

New ESMO urothelial cancer guidelines out. In M1 disease platinum based chemo and maintenance Avelumab is the preferred 1st line therapy [1A] . Then Enfortumab Vedotin as 2nd line [1A]. Erdafitinib is an option in FGFR patients [3b]. ESMO - Eur. Oncology annalsofoncology.org/article/S0923-…

thelancet.com/journals/lanon…

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023